JP2014509657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509657A5 JP2014509657A5 JP2014502871A JP2014502871A JP2014509657A5 JP 2014509657 A5 JP2014509657 A5 JP 2014509657A5 JP 2014502871 A JP2014502871 A JP 2014502871A JP 2014502871 A JP2014502871 A JP 2014502871A JP 2014509657 A5 JP2014509657 A5 JP 2014509657A5
- Authority
- JP
- Japan
- Prior art keywords
- vemurafenib
- acceptable salt
- pharmaceutically acceptable
- compound
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 44
- 229960003862 vemurafenib Drugs 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000011780 sodium chloride Substances 0.000 claims description 31
- 206010025650 Malignant melanoma Diseases 0.000 claims description 24
- 201000001441 melanoma Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 102200055464 BRAF V600E Human genes 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 238000009097 single-agent therapy Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 108091007934 protein kinase B family Proteins 0.000 claims description 6
- 230000002195 synergetic Effects 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 3
- 230000000051 modifying Effects 0.000 claims description 3
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 230000001394 metastastic Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 24
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 19
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 9
- 229960003668 docetaxel Drugs 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000000996 additive Effects 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 5
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 4
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000003463 hyperproliferative Effects 0.000 description 4
- 101700025368 ERBB2 Proteins 0.000 description 3
- 102100016662 ERBB2 Human genes 0.000 description 3
- 210000002307 Prostate Anatomy 0.000 description 3
- 101710037934 QRSL1 Proteins 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 229960001433 Erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 229940034727 Zelboraf Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 102100004328 BRAF Human genes 0.000 description 1
- 101700004551 BRAF Proteins 0.000 description 1
- 208000000409 Breast Neoplasms Diseases 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N Enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 201000000496 gastric squamous cell carcinoma Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
Description
ZELBORAF(登録商標)(ベムラフェニブ)(ジェネンテック社)は、米国で承認された薬物製品であり、FDAの承認を受けた試験により検出されるBRAF V600E変異を有する切除不能又は転移性メラノーマの患者の治療に適応される。ZELBORAF(登録商標)(ベムラフェニブ)は、BRAF V600E変異を欠くメラノーマ患者(野生型メラノーマ)における使用のためには推奨されない。
本発明の更なる特定の態様は、以下のとおりである。
態様1
過剰増殖性疾患の予防的又は治療的処置のための、a)式Iaの化合物
又はその薬学的に許容される塩;及びb)ベムラフェニブ又はその薬学的に許容される塩との組み合わせ。
態様2
過剰増殖性疾患が癌である、態様1に記載の組み合わせ。
態様3
癌がBRAF V600E変異を含む、態様2に記載の組み合わせ。
態様4
癌が高pAKT発現又は活性化レベルと関連付けられる、態様2又は3に記載の組み合わせ。
態様5
癌が、リンパ腫、結腸癌、メラノーマ、甲状腺癌又肺癌である、態様2から4の何れか一態様に記載の組み合わせ。
態様6
癌がベムラフェニブ単剤療法に耐性である、態様5に記載の組み合わせ。
態様7
癌が転移性又は切除不能なメラノーマである、態様6に記載の組み合わせ。
態様8
組み合わせが疾患の治療に相乗効果を与える、態様1から7の何れか一態様に記載の組み合わせ。
態様9
式Iaの化合物又はその塩がベムラフェニブ又はその塩と同時に投与される、態様1から7の何れか一態様に記載の組み合わせ。
態様10
式Iaの化合物又はその塩及びベムラフェニブ又はその塩が逐次に投与される、態様1から7の何れか一態様に記載の組み合わせ。
態様11
ベムラフェニブ又はその薬学的に許容される塩により過剰増殖性疾患を治療される患者の生活の質を改善するための治療的用途のために、態様1に記載される式Iaの化合物又はその薬学的に許容される塩。
態様12
a)態様1に記載される式Iaの化合物又はその薬学的に許容される塩、及びb)ベムラフェニブ又はその薬学的に許容される塩を哺乳動物に投与することを含む、哺乳動物においてBRAF V600E変異及び高pAKTレベルにより調節される疾患又は状態を治療するための方法。
態様13
患者がベムラフェニブ単剤療法を以前に受けている、態様12に記載の方法。
態様14
ベムラフェニブが哺乳動物に投与される、哺乳動物における過剰増殖性疾患の治療のための医薬の調製において、態様1に記載される式Iaの化合物又はその薬学的に許容される塩の使用。
態様15
ベムラフェニブが哺乳動物に投与される、哺乳動物におけるAKTキナーゼにより調節される疾患又は状態の治療のための医薬の調製において、態様1に記載される式Iaの化合物又はその薬学的に許容される塩の使用。
一般的調製方法
〔実施例〕
態様1
過剰増殖性疾患の予防的又は治療的処置のための、a)式Iaの化合物
又はその薬学的に許容される塩;及びb)ベムラフェニブ又はその薬学的に許容される塩との組み合わせ。
態様2
過剰増殖性疾患が癌である、態様1に記載の組み合わせ。
態様3
癌がBRAF V600E変異を含む、態様2に記載の組み合わせ。
態様4
癌が高pAKT発現又は活性化レベルと関連付けられる、態様2又は3に記載の組み合わせ。
態様5
癌が、リンパ腫、結腸癌、メラノーマ、甲状腺癌又肺癌である、態様2から4の何れか一態様に記載の組み合わせ。
態様6
癌がベムラフェニブ単剤療法に耐性である、態様5に記載の組み合わせ。
態様7
癌が転移性又は切除不能なメラノーマである、態様6に記載の組み合わせ。
態様8
組み合わせが疾患の治療に相乗効果を与える、態様1から7の何れか一態様に記載の組み合わせ。
態様9
式Iaの化合物又はその塩がベムラフェニブ又はその塩と同時に投与される、態様1から7の何れか一態様に記載の組み合わせ。
態様10
式Iaの化合物又はその塩及びベムラフェニブ又はその塩が逐次に投与される、態様1から7の何れか一態様に記載の組み合わせ。
態様11
ベムラフェニブ又はその薬学的に許容される塩により過剰増殖性疾患を治療される患者の生活の質を改善するための治療的用途のために、態様1に記載される式Iaの化合物又はその薬学的に許容される塩。
態様12
a)態様1に記載される式Iaの化合物又はその薬学的に許容される塩、及びb)ベムラフェニブ又はその薬学的に許容される塩を哺乳動物に投与することを含む、哺乳動物においてBRAF V600E変異及び高pAKTレベルにより調節される疾患又は状態を治療するための方法。
態様13
患者がベムラフェニブ単剤療法を以前に受けている、態様12に記載の方法。
態様14
ベムラフェニブが哺乳動物に投与される、哺乳動物における過剰増殖性疾患の治療のための医薬の調製において、態様1に記載される式Iaの化合物又はその薬学的に許容される塩の使用。
態様15
ベムラフェニブが哺乳動物に投与される、哺乳動物におけるAKTキナーゼにより調節される疾患又は状態の治療のための医薬の調製において、態様1に記載される式Iaの化合物又はその薬学的に許容される塩の使用。
一般的調製方法
〔実施例〕
Claims (22)
- ベムラフェニブと同時に投与される、請求項1の医薬。
- ベムラフェニブと逐次に投与される、請求項1の医薬。
- ベムラフェニブと別々に投与される、請求項1の医薬。
- メラノーマがBRAF V600E変異を含む、請求項1から4の何れか一項の医薬。
- メラノーマが高pAKT発現又は活性化レベルと関連付けられる、請求項1から5の何れか一項の医薬。
- メラノーマがベムラフェニブ単剤療法に耐性である、請求項1から6の何れか一項の医薬。
- メラノーマが転移性又は切除不能なメラノーマである、請求項7の医薬。
- 該医薬とベムラフェニブとの組み合わせが疾患の治療に相乗効果を与える、請求項1から8の何れか一項の医薬。
- 該化合物又その薬学的に許容される塩とベムラフェニブとが同時に投与される、請求項10の医薬。
- 該化合物又その薬学的に許容される塩とベムラフェニブとが逐次に投与される、請求項10の医薬。
- 該化合物又その薬学的に許容される塩とベムラフェニブとが別々に投与される、請求項10の医薬。
- a)該化合物又はその薬学的に許容される塩及びb)ベムラフェニブ又はその薬学的に許容される塩が同時に投与される、請求項15の医薬。
- a)該化合物又はその薬学的に許容される塩及びb)ベムラフェニブ又はその薬学的に許容される塩が逐次に投与される、請求項15の医薬。
- a)該化合物又はその薬学的に許容される塩及びb)ベムラフェニブ又はその薬学的に許容される塩が別々に投与される、請求項15の医薬。
- 患者がベムラフェニブ単剤療法を以前に受けている、請求項15の医薬。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470624P | 2011-04-01 | 2011-04-01 | |
US201161470803P | 2011-04-01 | 2011-04-01 | |
US61/470,803 | 2011-04-01 | ||
US61/470,624 | 2011-04-01 | ||
PCT/US2012/031665 WO2012135750A1 (en) | 2011-04-01 | 2012-03-30 | Combinations of akt inhibitor compounds and vemurafenib, and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014509657A JP2014509657A (ja) | 2014-04-21 |
JP2014509657A5 true JP2014509657A5 (ja) | 2016-09-15 |
JP6143739B2 JP6143739B2 (ja) | 2017-06-07 |
Family
ID=46931958
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014502876A Active JP6239497B2 (ja) | 2011-04-01 | 2012-03-30 | Akt阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法 |
JP2014502871A Active JP6143739B2 (ja) | 2011-04-01 | 2012-03-30 | Akt阻害剤化合物及びベムラフェニブの組み合わせ、及び使用方法 |
JP2014502886A Pending JP2014512356A (ja) | 2011-04-01 | 2012-03-30 | Akt阻害剤化合物及び化学療法剤の組み合わせ、及び使用方法 |
JP2014502873A Pending JP2014512354A (ja) | 2011-04-01 | 2012-03-30 | Akt阻害剤化合物及びエルロチニブの組み合わせ、及び使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014502876A Active JP6239497B2 (ja) | 2011-04-01 | 2012-03-30 | Akt阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014502886A Pending JP2014512356A (ja) | 2011-04-01 | 2012-03-30 | Akt阻害剤化合物及び化学療法剤の組み合わせ、及び使用方法 |
JP2014502873A Pending JP2014512354A (ja) | 2011-04-01 | 2012-03-30 | Akt阻害剤化合物及びエルロチニブの組み合わせ、及び使用方法 |
Country Status (27)
Country | Link |
---|---|
US (7) | US9150548B2 (ja) |
EP (4) | EP2694071B1 (ja) |
JP (4) | JP6239497B2 (ja) |
KR (4) | KR20140025434A (ja) |
CN (8) | CN103841975A (ja) |
AU (4) | AU2012236166A1 (ja) |
BR (4) | BR112013025354A2 (ja) |
CA (4) | CA2831937A1 (ja) |
DK (1) | DK2694072T3 (ja) |
ES (3) | ES2660263T3 (ja) |
HK (2) | HK1199244A1 (ja) |
HR (1) | HRP20180223T1 (ja) |
HU (1) | HUE036513T2 (ja) |
IL (4) | IL228638A0 (ja) |
LT (1) | LT2694072T (ja) |
ME (1) | ME02998B (ja) |
MX (4) | MX2013011327A (ja) |
MY (1) | MY179607A (ja) |
PL (2) | PL2694485T3 (ja) |
PT (1) | PT2694072T (ja) |
RS (1) | RS56759B1 (ja) |
RU (4) | RU2631240C2 (ja) |
SG (5) | SG194048A1 (ja) |
SI (1) | SI2694072T1 (ja) |
TR (1) | TR201802093T4 (ja) |
WO (4) | WO2012135750A1 (ja) |
ZA (4) | ZA201308065B (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
PT3289876T (pt) | 2008-06-16 | 2022-10-28 | Univ Tennessee Res Found | Compostos para o tratamento do câncer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
KR101875720B1 (ko) | 2011-01-10 | 2018-07-09 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
CN103298345B (zh) | 2011-01-11 | 2016-12-14 | 诺瓦蒂斯公司 | 组合 |
RU2631240C2 (ru) | 2011-04-01 | 2017-09-20 | Дженентек, Инк. | Комбинации соединений-ингибиторов акт и абиратерона, и способы применения |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
EP2827903A4 (en) * | 2012-03-23 | 2016-02-10 | Sloan Kettering Inst Cancer | POTENTIATING CYTOTOXICITY TO MEDIATION BY ANTIBODY-INDUCED SUPPLEMENT THROUGH PI3K INHIBITION |
CA2904338C (en) | 2013-03-05 | 2022-07-05 | University Of Tennessee Research Foundation | Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer |
CN103304404B (zh) * | 2013-05-30 | 2015-07-29 | 万华化学集团股份有限公司 | 一种2,2-二羟甲基丁酸的制备方法 |
RU2016116915A (ru) * | 2013-10-01 | 2017-11-13 | Новартис Аг | Комбинация |
EP4282973A3 (en) * | 2013-11-15 | 2024-03-27 | F. Hoffmann-La Roche AG | Processes for the preparation of pyrimidinylcyclopentane compounds |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015160986A2 (en) * | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3164129A1 (en) * | 2014-07-01 | 2017-05-10 | Friedrich Miescher Institute for Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
KR101689542B1 (ko) | 2015-01-15 | 2016-12-26 | 숭실대학교산학협력단 | 폐암치료 향상을 위한 제피티닙 또는 에를로티닙 나노복합체 |
EP3072528B1 (en) * | 2015-03-26 | 2017-07-05 | ratiopharm GmbH | Composition comprising vemurafenib and cationic copolymer based on methacrylates |
EP3280448B1 (en) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
WO2017095826A1 (en) * | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Combination therapy for treatment of melanoma |
WO2017120218A1 (en) * | 2016-01-04 | 2017-07-13 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of prostate cancer cells with fat oxidation inhibitors and enzalutamide |
US11621057B2 (en) * | 2016-04-08 | 2023-04-04 | Biodesix, Inc. | Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2019229765A1 (en) * | 2018-05-29 | 2019-12-05 | Council Of Scientific & Industrial Research, India | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof |
US11701356B2 (en) | 2018-12-19 | 2023-07-18 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor |
EP4013419A1 (en) * | 2019-08-12 | 2022-06-22 | F. Hoffmann-La Roche AG | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant |
US20220298619A1 (en) | 2019-09-13 | 2022-09-22 | Praxair S.T. Technology, Inc. | Methods for producing increased crystalline and dense improved coatings |
US20230190718A1 (en) * | 2020-05-19 | 2023-06-22 | Board Of Regents, The University Of Texas System | Methods for the treatment of pancreatitis and prevention of pancreatic cancer |
WO2023109540A1 (zh) * | 2021-12-17 | 2023-06-22 | 中国医药研究开发中心有限公司 | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2802005A (en) | 1957-08-06 | S-eluorourace | ||
US729332A (en) * | 1902-07-21 | 1903-05-26 | Frank C Guss | Animal catching and holding device. |
US2885396A (en) | 1957-03-21 | 1959-05-05 | Heidelberger Charles | N-glycosides of 5-fluorouracil |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3885035A (en) | 1972-04-05 | 1975-05-20 | Sandoz Ag | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines |
CH605550A5 (ja) | 1972-06-08 | 1978-09-29 | Research Corp | |
US3956495A (en) | 1973-10-30 | 1976-05-11 | Eli Lilly And Company | 2,4-Diaminoquinazolines as antithrombotic agents |
US3966936A (en) | 1974-02-21 | 1976-06-29 | Pfizer Inc. | Piperazino quinazoline bronchodilators |
US4060615A (en) | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体 |
JPS562968A (en) | 1979-06-21 | 1981-01-13 | Mitsubishi Yuka Yakuhin Kk | Novel pyrimidine derivative |
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
EP0184365B1 (en) | 1984-12-04 | 1993-08-04 | Eli Lilly And Company | Improvements in the treatment of tumors in mammals |
JPS6270A (ja) | 1985-03-07 | 1987-01-06 | Sankyo Co Ltd | シクロペンタ〔d〕ピリミジン誘導体 |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
EP0799617A3 (en) | 1986-02-24 | 1997-11-12 | Mitsui Petrochemical Industries, Ltd. | Therapeutic agent for neurological diseases |
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
US4871739A (en) | 1987-01-21 | 1989-10-03 | Merck & Co., Inc. | Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents |
US4889856A (en) | 1987-08-31 | 1989-12-26 | Merck & Co., Inc. | 7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers |
US4994464A (en) | 1987-08-31 | 1991-02-19 | Merck & Co., Inc. | Piperazinylpyrimidines as β-adrenergic receptor blockers |
WO1990007926A1 (en) | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
DK0664291T3 (da) | 1992-10-05 | 2000-10-30 | Ube Industries | Pyrimidinforbindelse |
DE69232539T3 (de) | 1992-10-28 | 2007-01-04 | Genentech, Inc., South San Francisco | Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
AU688087B2 (en) | 1994-08-13 | 1998-03-05 | Yuhan Corporation | Novel pyrimidine derivatives and processes for the preparation thereof |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US7294332B2 (en) | 1995-10-04 | 2007-11-13 | Schering Corporation | Combination therapy (temozolomide and α-IFN) for advanced cancer |
ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
SI1325932T1 (ja) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
DE69841815D1 (de) | 1997-04-07 | 2010-09-16 | Genentech Inc | Anti-VEGF Antikörper |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
DE69836378T2 (de) | 1997-07-01 | 2007-10-11 | Warner-Lambert Co. Llc | Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren |
PT993439E (pt) | 1997-07-01 | 2004-12-31 | Warner Lambert Co | Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
DE19853278A1 (de) | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE69924641D1 (de) | 1999-01-07 | 2005-05-12 | Warner Lambert Company Llc Mor | Behandlung von asthma anhand von mek-inhibitoren |
JP2002534381A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いた抗ウィルス法 |
ATE309205T1 (de) | 1999-01-13 | 2005-11-15 | Warner Lambert Co | Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren |
WO2000042002A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
BR9916904A (pt) | 1999-01-13 | 2001-10-30 | Warner Lambert Co | Benzo heterociclos e seu uso como inibidores demek |
WO2000042029A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
JP2002534446A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 4′ヘテロアリールジアリールアミン |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
US9534254B1 (en) * | 1999-02-02 | 2017-01-03 | Abbott Molecular Inc. | Patient stratification for cancer therapy based on genomic DNA microarray analysis |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
WO2001004111A1 (en) | 1999-07-09 | 2001-01-18 | Glaxo Group Limited | Anilinoquinazolines as protein tyrosine kinase inhibitors |
EP1202731A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
HUP0202623A3 (en) | 1999-07-16 | 2003-03-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いる慢性疼痛の治療方法 |
WO2001005391A2 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
TW200914443A (en) | 2000-06-30 | 2009-04-01 | Glaxo Group Ltd | Process for preparing substituted quinazolinyl furanaldehyde |
CN1219753C (zh) | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4-碘苯氨基苯氧肟酸的氧合酯 |
CN1458921A (zh) | 2000-08-25 | 2003-11-26 | 沃尼尔·朗伯有限责任公司 | N-芳基邻氨基苯甲酸和它们的衍生物的制备方法 |
WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
EP1353693B1 (en) | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
EP1383747B1 (en) | 2001-04-30 | 2008-02-20 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
NZ518726A (en) | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
DE60231439D1 (de) | 2001-12-06 | 2009-04-16 | Merck & Co Inc | Mitotische kinesinhemmer |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003062225A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
CN1652792A (zh) | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
HUE025767T2 (en) | 2002-03-13 | 2016-05-30 | Array Biopharma Inc | N3-alkylated benzimidazole derivatives as MEK inhibitors |
WO2003086404A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
CA2480800C (en) | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity |
US20050130977A1 (en) | 2002-04-08 | 2005-06-16 | Lindsley Craig W. | Inhibitors of akt activity |
AU2003226250B2 (en) | 2002-04-08 | 2007-08-16 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
EP1503761A1 (en) | 2002-05-10 | 2005-02-09 | Neurocrine Biosciences, Inc. | Substituted piperazines as melanocortin receptor ligands |
AU2003284981B2 (en) | 2002-10-30 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
MXPA05003431A (es) | 2002-11-15 | 2005-07-05 | Warner Lambert Co | Quimioterapia de combinacion. |
NZ539823A (en) | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
EP1620095A4 (en) | 2003-04-24 | 2009-04-01 | Merck & Co Inc | INHIBITORS OF AKT ACTIVITY |
KR20060006975A (ko) | 2003-05-30 | 2006-01-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
EP1646615B1 (en) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
AR045134A1 (es) | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
NZ545717A (en) | 2003-08-05 | 2009-12-24 | Vertex Pharma | Hydrogenated quinazoline derivatives as inhibitors of voltage-gated ion channels |
JP2007501821A (ja) | 2003-08-12 | 2007-02-01 | エフ.ホフマン−ラ ロシュ アーゲー | Cfrアンタゴニストとしてのテトラヒドロキナゾリン誘導体 |
AU2004272437A1 (en) | 2003-09-09 | 2005-03-24 | Ono Pharmaceutical Co., Ltd. | CRF antagonists and heterobicyclic compounds |
WO2005039564A1 (en) | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
EP1684694A2 (en) | 2003-11-21 | 2006-08-02 | Array Biopharma, Inc. | Akt protein kinase inhibitors |
PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
WO2005094322A2 (en) | 2004-03-29 | 2005-10-13 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
CA2570552A1 (en) | 2004-06-28 | 2006-01-05 | Altana Pharma Ag | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
US20060025074A1 (en) | 2004-07-30 | 2006-02-02 | Chih-Ming Liang | Bluetooth-based headset |
TWM266655U (en) | 2004-09-23 | 2005-06-01 | Blueexpert Technology Corp | Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal |
TW200621257A (en) | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
WO2006094230A2 (en) | 2005-03-03 | 2006-09-08 | The Burnham Institute For Medical Research | Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
US7863288B2 (en) * | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
CA2625109A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
US7960545B2 (en) | 2005-11-23 | 2011-06-14 | Natco Pharma Limited | Process for the prepartion of erlotinib |
CA2635541A1 (en) | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
EP1990253B1 (en) | 2006-03-02 | 2019-06-12 | NSK Ltd. | Torque sensor |
JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
EP2054418B1 (en) | 2006-07-06 | 2011-11-09 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
CA2656618C (en) | 2006-07-06 | 2014-08-26 | Array Biopharma Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
EP2049478B1 (en) | 2006-07-06 | 2012-05-30 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
UA95641C2 (en) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
GB0613518D0 (en) | 2006-07-06 | 2006-08-16 | Phytopharm Plc | Chemical compounds |
WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
EP2049541B1 (en) * | 2006-08-04 | 2015-09-23 | Takeda Pharmaceutical Company Limited | N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1h-pyrazole-5-carboxamide as vegfr inhibitor |
EP3804730A1 (en) | 2006-08-25 | 2021-04-14 | Janssen Oncology, Inc. | Compositions for treating cancer |
WO2008094321A2 (en) | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Akt sensitization of cancer cells |
CN101332301A (zh) * | 2007-06-26 | 2008-12-31 | 南京医科大学 | 一种抗肿瘤组合物及其应用 |
EP2170062A4 (en) | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES |
AU2008274956B2 (en) | 2007-07-12 | 2014-08-21 | University Of South Florida | Inhibitors of Akt/PKB with anti-tumor activity |
US8137919B2 (en) * | 2008-04-10 | 2012-03-20 | Montefiore Medical Center | Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib |
WO2010012777A1 (en) * | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
EP2318377B1 (en) * | 2008-07-31 | 2013-08-21 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
PL2694959T3 (pl) * | 2011-04-01 | 2020-05-18 | Genentech, Inc. | Biomarkery do przewidywania wrażliwości w leczeniu nowotworu złośliwego |
RU2631240C2 (ru) | 2011-04-01 | 2017-09-20 | Дженентек, Инк. | Комбинации соединений-ингибиторов акт и абиратерона, и способы применения |
-
2012
- 2012-03-30 RU RU2013148815A patent/RU2631240C2/ru active
- 2012-03-30 CA CA2831937A patent/CA2831937A1/en not_active Abandoned
- 2012-03-30 SG SG2013073747A patent/SG194048A1/en unknown
- 2012-03-30 MX MX2013011327A patent/MX2013011327A/es not_active Application Discontinuation
- 2012-03-30 WO PCT/US2012/031665 patent/WO2012135750A1/en active Application Filing
- 2012-03-30 EP EP12764184.3A patent/EP2694071B1/en active Active
- 2012-03-30 CN CN201280026870.5A patent/CN103841975A/zh active Pending
- 2012-03-30 BR BR112013025354A patent/BR112013025354A2/pt not_active IP Right Cessation
- 2012-03-30 CN CN202110099289.7A patent/CN112915092A/zh active Pending
- 2012-03-30 JP JP2014502876A patent/JP6239497B2/ja active Active
- 2012-03-30 US US14/009,310 patent/US9150548B2/en active Active
- 2012-03-30 BR BR112013025386-0A patent/BR112013025386B1/pt active IP Right Grant
- 2012-03-30 ME MEP-2018-22A patent/ME02998B/me unknown
- 2012-03-30 MX MX2013011329A patent/MX2013011329A/es not_active Application Discontinuation
- 2012-03-30 KR KR1020137029099A patent/KR20140025434A/ko not_active Application Discontinuation
- 2012-03-30 BR BR112013025355-0A patent/BR112013025355B1/pt active IP Right Grant
- 2012-03-30 US US14/009,314 patent/US20150064171A1/en not_active Abandoned
- 2012-03-30 WO PCT/US2012/031720 patent/WO2012135781A1/en active Application Filing
- 2012-03-30 TR TR2018/02093T patent/TR201802093T4/tr unknown
- 2012-03-30 EP EP12764765.9A patent/EP2694072B1/en active Active
- 2012-03-30 EP EP12763771.8A patent/EP2694070A4/en not_active Withdrawn
- 2012-03-30 KR KR1020137029063A patent/KR102021157B1/ko active IP Right Grant
- 2012-03-30 MX MX2013011332A patent/MX354509B/es active IP Right Grant
- 2012-03-30 WO PCT/US2012/031671 patent/WO2012135753A1/en active Application Filing
- 2012-03-30 KR KR1020137029093A patent/KR101950044B1/ko active IP Right Grant
- 2012-03-30 PL PL12765234T patent/PL2694485T3/pl unknown
- 2012-03-30 CN CN201710422676.3A patent/CN107233343A/zh active Pending
- 2012-03-30 ES ES12764765.9T patent/ES2660263T3/es active Active
- 2012-03-30 RU RU2013148732/04A patent/RU2013148732A/ru not_active Application Discontinuation
- 2012-03-30 CN CN202010686337.8A patent/CN111643504A/zh active Pending
- 2012-03-30 CN CN201280026871.XA patent/CN103874689B/zh active Active
- 2012-03-30 DK DK12764765.9T patent/DK2694072T3/en active
- 2012-03-30 CN CN201280027028.3A patent/CN103635192B/zh active Active
- 2012-03-30 LT LTEP12764765.9T patent/LT2694072T/lt unknown
- 2012-03-30 PL PL12764765T patent/PL2694072T3/pl unknown
- 2012-03-30 RU RU2013148728/04A patent/RU2013148728A/ru not_active Application Discontinuation
- 2012-03-30 CN CN201280026868.8A patent/CN103857395A/zh active Pending
- 2012-03-30 JP JP2014502871A patent/JP6143739B2/ja active Active
- 2012-03-30 MY MYPI2013003572A patent/MY179607A/en unknown
- 2012-03-30 WO PCT/US2012/031679 patent/WO2012135759A1/en active Application Filing
- 2012-03-30 AU AU2012236166A patent/AU2012236166A1/en not_active Abandoned
- 2012-03-30 SG SG2013073788A patent/SG194052A1/en unknown
- 2012-03-30 US US14/009,316 patent/US9346789B2/en active Active
- 2012-03-30 PT PT127647659T patent/PT2694072T/pt unknown
- 2012-03-30 CA CA2831922A patent/CA2831922C/en active Active
- 2012-03-30 BR BR112013025353A patent/BR112013025353A8/pt not_active Application Discontinuation
- 2012-03-30 AU AU2012236135A patent/AU2012236135A1/en not_active Abandoned
- 2012-03-30 SI SI201231202T patent/SI2694072T1/en unknown
- 2012-03-30 ES ES12764184.3T patent/ES2620644T3/es active Active
- 2012-03-30 JP JP2014502886A patent/JP2014512356A/ja active Pending
- 2012-03-30 KR KR1020137029130A patent/KR20140021646A/ko not_active Application Discontinuation
- 2012-03-30 US US14/009,313 patent/US9150549B2/en active Active
- 2012-03-30 ES ES12765234.5T patent/ES2657750T3/es active Active
- 2012-03-30 HU HUE12764765A patent/HUE036513T2/hu unknown
- 2012-03-30 SG SG10201504303SA patent/SG10201504303SA/en unknown
- 2012-03-30 RU RU2013148721/04A patent/RU2013148721A/ru not_active Application Discontinuation
- 2012-03-30 SG SG2013073770A patent/SG194051A1/en unknown
- 2012-03-30 SG SG2013073713A patent/SG194045A1/en unknown
- 2012-03-30 AU AU2012236138A patent/AU2012236138A1/en not_active Abandoned
- 2012-03-30 MX MX2013011330A patent/MX351892B/es active IP Right Grant
- 2012-03-30 CA CA2844699A patent/CA2844699C/en active Active
- 2012-03-30 EP EP12765234.5A patent/EP2694485B1/en active Active
- 2012-03-30 CA CA2831935A patent/CA2831935A1/en not_active Abandoned
- 2012-03-30 RS RS20180052A patent/RS56759B1/sr unknown
- 2012-03-30 AU AU2012236144A patent/AU2012236144B2/en active Active
- 2012-03-30 JP JP2014502873A patent/JP2014512354A/ja active Pending
- 2012-03-30 CN CN201410778065.9A patent/CN104586861A/zh active Pending
-
2013
- 2013-09-30 IL IL228638A patent/IL228638A0/en unknown
- 2013-09-30 IL IL228637A patent/IL228637B/en active IP Right Grant
- 2013-09-30 IL IL228641A patent/IL228641A0/en unknown
- 2013-09-30 IL IL228642A patent/IL228642A0/en unknown
- 2013-10-29 ZA ZA2013/08065A patent/ZA201308065B/en unknown
- 2013-10-29 ZA ZA2013/08062A patent/ZA201308062B/en unknown
- 2013-10-29 ZA ZA2013/08064A patent/ZA201308064B/en unknown
- 2013-11-01 ZA ZA2013/08198A patent/ZA201308198B/en unknown
-
2014
- 2014-12-18 HK HK14112699.3A patent/HK1199244A1/zh unknown
-
2015
- 2015-06-01 HK HK15105215.1A patent/HK1204575A1/xx unknown
- 2015-08-26 US US14/836,827 patent/US9610289B2/en active Active
-
2016
- 2016-02-05 US US15/017,315 patent/US9717730B2/en active Active
-
2017
- 2017-02-21 US US15/438,277 patent/US10092567B2/en active Active
-
2018
- 2018-02-06 HR HRP20180223TT patent/HRP20180223T1/hr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014509657A5 (ja) | ||
AU2020222296B2 (en) | Pharmaceutical combination comprising TNO155 and ribociclib | |
JP5931982B2 (ja) | (a)ホスホイノシタイド3−キナーゼ阻害剤および(b)Ras/Raf/Mek経路のモジュレーターの配合物 | |
US8383607B2 (en) | Perifosine and capecitabine as a combined treatment for cancer | |
JP7278331B2 (ja) | がんの処置において使用するための、Notch阻害剤およびPI3K/mTOR阻害剤を用いた併用療法 | |
JP2014512356A5 (ja) | ||
AU2012321110A1 (en) | Combination treatment | |
JP2012515184A (ja) | 大腸がんの治療方法 | |
WO2016160102A1 (en) | Active metabolites of apilimod and uses thereof | |
JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
JP2014512355A5 (ja) | ||
CA2726644A1 (en) | Pharmaceutical combination comprising 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and pemetrexed, and use thereof in cancer treatment | |
JP2024056686A (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 | |
JP6080837B2 (ja) | 療法的治療 | |
JP2016520662A (ja) | Pi3k阻害剤および微小管不安定化剤の医薬組み合わせ | |
EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
JP6243850B2 (ja) | 抗がん剤による末梢神経障害の予防、治療、または軽減剤 | |
Schöffski et al. | Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer | |
Ohana et al. | Adjusted Dosing and Schedule of Pemetrexed in Impaired Renal Function. | |
MX2013013406A (es) | Medicamentos y metodos para tratar cancer. | |
Vidula | Regaining Control of the Cell Cycle With CDK 4/6 Inhibitors: A Promising Targeted Therapy for Breast Cancer | |
TW201313225A (zh) | 與放射線治療關聯之包含奧瑞布林(ombrabulin)及順鉑(cisplatin)之抗腫瘤組合 | |
NZ619009B2 (en) | Medicaments and methods for treating cancer |